Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11514119 | 0.83 | TDP1 (0.55) | ALDH1A1TP53NPC1MAPTTDP1 | |
| SCHEMBL102139 | 0.81 | TDP1 (0.36) | ALDH1A1TP53NPC1TDP1CYP3A4 | |
| SCHEMBL9794569 | 0.78 | NOTUM (0.35) | NOTUMMCL1ALDH1A1TP53USP2 | |
| SCHEMBL7049757 | 0.78 | ACHE (0.38) | ALDH1A1TP53TDP1CYP3A4 | |
| SCHEMBL5779452 | 0.78 | ACHE (0.44) | NOTUMALDH1A1TP53NPC1MAPT | |
| SCHEMBL10941967 | 0.77 | AHR (0.46) | NOTUMNPC1USP2MAPTRAB9A | |
| SCHEMBL2434582 | 0.77 | NFE2L2 (0.35) | NOTUMALDH1A1PTGS2 | |
| SCHEMBL7138582 | 0.77 | ACHE (0.36) | ALDH1A1TSHR | |
| SCHEMBL2154312 | 0.76 | AHR (0.34) | NOTUMALDH1A1TP53NPC1MAPT | |
| SCHEMBL1141083 | 0.76 | NPC1 (0.39) | NOTUMMCL1ALDH1A1NPC1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | US | claimed |
| WO-2009059272-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | WO | claimed |
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | US | disclosed |
| WO-2009059272-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | WYETH (US) | 2009-05-07 | — | — | WO | disclosed |
| EP-0869765-A1 | AQUEOUS NAIL COATING COMPOSITION CONTAINING COPOLYMERIZED COLORANTS | EASTMAN CHEMICAL COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5749925-A | Dyeing or printing process with new and known cationic 4,5-dihydro-iH-1,2,3-triazolium compounds as dyestuffs and new cationic 4,5-dihydro-1H-1,2,3-triazolium compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1998-05-12 | — | — | US | disclosed |
| WO-1997024102-A1 | AQUEOUS NAIL COATING COMPOSITION CONTAINING COPOLYMERIZED COLORANTS | EASTMAN CHEMICAL COMPANY (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118276-A1 | THIENOPYRIMIDINES, THIENOPYRIDINES, AND PYRROLOPYRIMIDINES AS B-RAF INHIBITORS | BRAF, ARAF, RAF1 | NOTUM 4504/4885MCL1 1283/4885ALDH1A1 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.